NICE does not recommend Ocrevus for primary progressive MS.- Roche
The National Institute for Health and Care Excellence (NICE) finalized its decision not to recommend coverage of Roche's Ocrevus (ocrelizumab) in primary progressive multiple sclerosis (MS). NICE had reversed an earlier recommendation for relapsing MS, but only for patients who were not able to take Lemtrada and who could obtain the drug through a discount patient access scheme.
NICE could not recommend Ocrevus for primary progressive MS as the cost-effectiveness estimates for the drug in this indication compared with best supportive care alone are much higher than those NICE normally considers an acceptable use of limited NHS resources.
160 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.